Research · 9 min read
When a Visit Has to Happen in a Room
Federal law names an in-person requirement in a small number of places and defines the phrase precisely. Reading where those requirements actually reach explains a great deal about why this category is delivered the way it is.
Key takeaways
- Federal law defines an in-person medical evaluation as one conducted with the patient in the physical presence of the practitioner, and applies that requirement to controlled substances dispensed over the Internet.
- The same statute refuses to let one in-person visit prove that a prescription was legitimate, calling presence a threshold rather than a verdict.
- A covering practitioner may evaluate remotely, but only downstream of a relationship anchored by an in-person or telemedicine evaluation within the previous twenty-four months.
- A name census of the five federal controlled substance schedule sections did not return semaglutide, tirzepatide or liraglutide, with known scheduled substances appearing where expected in the same search.
- The one recurring federal in-person requirement in telehealth is a Medicare payment condition for mental health services beginning in January 2028.
- Federal law pays a distant-site practitioner the same amount as if the service had been furnished without a telecommunications system.
Answer first: the two federal in-person rules are narrower than people assume
There is a widespread belief that a prescription written after an online form is a loophole. The real position is more specific and more interesting.
Federal law does impose an in-person requirement in this area, and it does it in two places. One is about controlled substances. The other is about mental health services under one federal payer.
Both are written tightly, and both are worth reading rather than summarizing, because the exact words explain the shape of the market that grew up around them.
Where a requirement does not reach, the question is not settled in the program's favor. It simply moves to state law and to the program's own design.
The controlled substance rule, and the definition underneath it
The statute says that no controlled substance that is a prescription drug may be delivered, distributed or dispensed by means of the Internet without a valid prescription.
It then defines valid prescription for that purpose. It means a prescription issued for a legitimate medical purpose in the usual course of professional practice. The person issuing it must be a practitioner who has conducted at least one in-person medical evaluation of the patient, or a covering practitioner.
The definition of in-person medical evaluation is the part worth quoting. It means a medical evaluation conducted with the patient in the physical presence of the practitioner, without regard to whether portions of the evaluation are conducted by other health professionals.
Two things follow from that wording. Physical presence is the test, and it is the presence of the practitioner specifically. Other health professionals may carry out parts of the evaluation without breaking it.
The statute then adds a caveat that is easy to miss and hard to overstate. Nothing in that clause is to be construed to imply that one in-person medical evaluation demonstrates that a prescription was issued for a legitimate medical purpose in the usual course of professional practice.
In other words, being in the room is a floor and not a certificate. The statute refuses to let a single physical visit stand in for the judgment it is meant to support.
The covering practitioner, and the clock attached to it
The statute contemplates that the person evaluating you may not be the person who saw you. It calls that role a covering practitioner and defines it carefully.
A covering practitioner conducts an evaluation other than an in-person one, at the request of another practitioner. That requesting practitioner must have conducted an in-person medical evaluation, or an evaluation through the practice of telemedicine, within the previous twenty-four months.
The requesting practitioner also has to be temporarily unavailable. Covering is designed as a gap-filling role rather than as a standing arrangement.
So the statute allows a remote evaluation by someone who has never met you, but only downstream of a relationship that has an in-person or telemedicine anchor and a two-year clock on it.
The related definition of the practice of telemedicine is narrower still in one branch. It contemplates a practitioner remote from the patient, while the patient is being treated by and physically located in a registered hospital or clinic. The practitioner must be registered in the state where the patient is located.
Whether that rule reaches this category
The requirement is written about controlled substances, so the question is whether these medications are scheduled.
The five sections of federal regulation that list the controlled substance schedules were read in one pass and searched by name. Semaglutide, tirzepatide and liraglutide do not appear in any of the five.
The same search found the substances you would expect where you would expect them, which is how the zero was checked rather than trusted. That is a census of the listing sections by ingredient name, and it is worth stating as exactly that rather than as a broader legal opinion.
The practical consequence is straightforward. The in-person medical evaluation requirement in that statute is not what governs a prescription in this category.
A program that never asks you into a room is not, on that basis, evading a federal rule. The federal rule was written about a different problem.
The other in-person anchor, and what it is really about
The second place federal law reaches for an in-person visit sits in the Medicare telehealth payment provisions, and it applies to mental health.
The statute bars payment for telehealth services furnished from January 2028 for the diagnosis, evaluation or treatment of a mental health disorder. The bar lifts where the same practitioner furnishes an item or service in person, without the use of telehealth. That in-person service must fall within the six-month period before the first such telehealth service, and must recur during subsequent periods.
Read it as an anchoring rule rather than a ban. Remote care is permitted and paid; what the statute requires is that a physical encounter exist near the start and recur.
It is also a payment condition rather than a licensing rule. It tells you what one payer will pay for, which is a narrower thing than what a clinician may do.
There is a parallel provision for federally qualified health centers, where an in-person mental health visit requirement is suspended until the same period. Congress has legislated on this repeatedly, which tells you the question is regarded as unsettled rather than closed.
What federal law assumes a remote visit is worth
One provision answers that question in money, which is the bluntest form an answer can take.
The Medicare telehealth payment rule directs that a practitioner at a distant site be paid a specific amount. It is the amount that would have been paid had the service been furnished without a telecommunications system.
That is a deliberate equivalence. For the services on the covered list, the statute treats a remote encounter as the same service rather than a discounted version of one.
The same subsection is also where federal law defines store-and-forward technology, describing it as providing for the asynchronous transmission of health care information in single or multimedia formats. That definition appears inside a narrow demonstration provision, which is itself telling about how the general rule is framed.
Taken together the picture is consistent. Federal law generally treats a real-time remote encounter as a visit, and reserves the in-person requirement for specific categories where it decided the stakes justified one.
What is left to decide, and who decides it
Where the two federal requirements do not reach, the requirement comes from somewhere else. State law and professional boards set the standards for how a patient relationship is established, and they do not all set them the same way.
That is why the same program can operate differently depending on where you are, and why availability lists are state by state rather than national.
The program's own design is the other half. Nothing stops a program from requiring more than the law requires, and some structures do.
The checkable version of the question is not whether a visit is legally required. It is what the program does before it decides about you, and whether it says so in advance.
A program that describes its own process concretely has given you something to compare. One that describes it only as a review has not.
Sources
- 21 U.S.C. 829 — PrescriptionsThe rule that no controlled substance which is a prescription drug may be delivered, distributed or dispensed by means of the Internet without a valid prescription; the definition of valid prescription as one issued for a legitimate medical purpose in the usual course of professional practice by a practitioner who has conducted at least one in-person medical evaluation, or by a covering practitioner; the definition of in-person medical evaluation as a medical evaluation conducted with the patient in the physical presence of the practitioner, without regard to whether portions of the evaluation are conducted by other health professionals; the express statement that nothing in that clause implies that one in-person medical evaluation demonstrates that a prescription was issued for a legitimate medical purpose within the usual course of professional practice; and the definition of covering practitioner, including the requirement that the requesting practitioner have conducted an in-person medical evaluation or an evaluation through the practice of telemedicine within the previous twenty-four months and be temporarily unavailable.
- 21 U.S.C. 802 — DefinitionsThe definition of the practice of telemedicine as the practice of medicine, in accordance with applicable federal and state laws, by a practitioner other than a pharmacist who is at a location remote from the patient and communicating with the patient or with a health care professional treating the patient using a telecommunications system referred to in the Medicare telehealth provision; and the branch of that definition requiring that the patient be treated by, and physically located in, a registered hospital or clinic, with the practitioner acting in the usual course of professional practice, acting in accordance with applicable state law, and registered in the state in which the patient is located unless exempted.
- 42 U.S.C. 1395m — Special payment rules for particular items and servicesThe direction that a physician or practitioner at a distant site furnishing a telehealth service be paid an amount equal to the amount that would have been paid had the service been furnished without the use of a telecommunications system; the description of store-and-forward technologies as providing for the asynchronous transmission of health care information in single or multimedia formats, appearing in the demonstration-program clause of that subsection; the bar on payment for telehealth services furnished on or after January 2028 for the diagnosis, evaluation or treatment of a mental health disorder unless the practitioner furnishes an in-person item or service within the six-month period prior to the first such telehealth service and during subsequent periods; and the parallel provision suspending, until the same period, the in-person mental health visit requirement applicable to federally qualified health centers.
- 21 CFR 1308.11 — Schedule IOne of the five listing sections searched by ingredient name for semaglutide, tirzepatide and liraglutide, none of which appears in it, in a pass whose positive controls fired as expected.
- 21 CFR 1308.12 — Schedule IIOne of the five listing sections searched by ingredient name for semaglutide, tirzepatide and liraglutide, none of which appears in it.
- 21 CFR 1308.13 — Schedule IIIOne of the five listing sections searched by ingredient name for semaglutide, tirzepatide and liraglutide, none of which appears in it.
- 21 CFR 1308.14 — Schedule IVOne of the five listing sections searched by ingredient name for semaglutide, tirzepatide and liraglutide, none of which appears in it.
- 21 CFR 1308.15 — Schedule VOne of the five listing sections searched by ingredient name for semaglutide, tirzepatide and liraglutide, none of which appears in it.
Frequently asked questions
Does federal law require an in-person visit before this kind of prescription?
The main federal in-person requirement in this area is written about controlled substances, and it requires a practitioner who has conducted at least one in-person medical evaluation, or a covering practitioner. A name census across the five federal sections listing the controlled substance schedules did not find semaglutide, tirzepatide or liraglutide in any of them, with known scheduled substances appearing where expected in the same search. So that requirement is not what governs a prescription here. What applies instead comes from state law and from the program's own process.
What counts as an in-person medical evaluation?
The statute defines it as a medical evaluation conducted with the patient in the physical presence of the practitioner, without regard to whether portions of the evaluation are conducted by other health professionals. Two things sit inside that. Physical presence is the test, so a call or a form does not satisfy it. And the presence that matters is the practitioner's, while other health professionals may perform parts of the evaluation without breaking the definition.
Does one in-person visit make a prescription valid?
The statute says the opposite in as many words. It states that nothing in the in-person clause implies a conclusion about the prescription itself. One in-person medical evaluation does not demonstrate that a prescription was issued for a legitimate medical purpose within the usual course of professional practice. Presence is a threshold, not a verdict. That is a useful corrective in both directions, since it also means an in-person visit is not automatically better evidence of careful prescribing than a thorough remote one.
What is a covering practitioner?
It is a defined role for the clinician who evaluates you when your own practitioner is temporarily unavailable. Under the statute a covering practitioner conducts an evaluation other than an in-person one, at the request of another practitioner. That requesting practitioner must have conducted an in-person medical evaluation, or one through the practice of telemedicine, within the previous twenty-four months. The design is a gap filler resting on an existing relationship, with a two-year clock attached to that relationship.
Is there any federal rule requiring a periodic in-person visit in telehealth?
There is one, and it is narrow. A Medicare payment provision bars payment for telehealth furnished from January 2028 for the diagnosis, evaluation or treatment of a mental health disorder. The bar lifts where the practitioner furnishes an in-person item or service within the six months before the first telehealth service, and again during subsequent periods. It is a payment condition for one payer and one category of care, not a general licensing rule, and it does not reach weight management.
Does the law treat a remote visit as a lesser visit?
For payment purposes it explicitly does not. The Medicare telehealth provision directs that a practitioner at a distant site be paid an amount equal to what would have been paid had the service been furnished without a telecommunications system. That is an equivalence written into the statute for the services on the covered list. Where the law wants a physical encounter, it says so specifically rather than by discounting remote care generally.